European Union & European Union — European Medicines Agency
8 shared events · Importance 11 · Last updated Jun 26, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
European Union: The European Union is the region where the marketing authorization for TAVNEOS is being revoked, affecting patients and pharmaceutical companies operating within its borders.
European Union — European Medicines Agency: The European Union — European Medicines Agency's CHMP recommended the revocation of the marketing authorization for TAVNEOS, impacting its availability in the EU.
Jun 26, 2026 · 9 articles
Regulatory
European Union: The European Union represents the market where DAYBU is seeking approval, and its member states will be affected by the potential marketing authorization.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is the overarching regulatory body whose CHMP adopted the positive opinion for DAYBU, facilitating its potential market entry in the EU.
Jun 26, 2026 · 6 articles
Business
European Union: The European Union>>> is a key region where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
May 19, 2026 · 7 articles
Regulatory
European Union: The European Union is a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the region.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent for chronic spontaneous urticaria (CSU) in the European Union.
Feb 24, 2026 · 8 articles
NEWSDESK
Explore this relationship live
Track how European Union and European Union — European Medicines Agency interact across events, view sentiment trends, and discover connected entities.
Open Dashboard